Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Hazaa Al Zahrani, Ruah Al Yamany, Mostafa Saleh, Saud Alhayli, Zakia Al Somali, Ahmad Alotaibi, AlFadel AlShaibani, Farah Deeba, Maryam Asif, Syed Ahmed Osman Ali Ahmed, Feras Al Fraih, Marwan Shaheen, Ali Alahmari, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Mahmoud Aljurf, Amr Hanbali
BACKGROUND: Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d: low dose dexamthasone) regimen is widely used due to its high effectiveness, low toxicity and good tolerability, particularly with renal impairment. Real-world data on the use of VCD in clinical practice is lacking. OBJECTIVES: Evaluate the real-world experience of the VCD regimen. DESIGN: Retrospective...
2024: Annals of Saudi Medicine